Designing Psychedelic Science for Women: Why Sex and Hormones Can No Longer Be Ignored

Clinical research is designed to detect signal – to determine whether an intervention truly works. Variability is the enemy of that signal. And few sources of variability are as powerful, or as routinely ignored, as female hormonal biology.

Women are not a biologically uniform group. Hormonal states fluctuate across the menstrual cycle, change profoundly during perimenopause and menopause, and vary further with contraception or hormone replacement therapy. These shifts influence brain function, emotional processing, stress responsivity, and neuroplasticity – all core mechanisms through which psychedelics exert their effects.

When trials fail to account for this, they introduce excess noise into the data. If some women respond more strongly to a psychedelic intervention during specific hormonal windows, while others respond differently at other times, collapsing those responses into a single average inflates variability and shrinks apparent effect sizes. A real therapeutic signal can disappear into statistical blur.

What looks like “no effect” may not mean the treatment failed. It may mean the study design was never capable of seeing it. The same is true here when we do simple male versus female analysis, what may not statistically seem significant a difference, in fact is when hormonal states for instance are considered.

The evidence is clear: inclusion is not the same as design

If we still needed proof that simply enrolling women is not enough, large-scale data now make this unmistakable.

Across 182 diseases analysed globally, women’s share of disease burden diverges meaningfully from prevalence in more than a quarter of conditions – indicating differences in severity, progression, and lived impact that prevalence alone does not capture. Equal numbers do not mean equal biology, nor equal therapeutic need.

Yet clinical trial design continues to rely on blunt enrolment targets rather than biologically informed stratification. Between 2015 and 2024, women were underrepresented relative to disease prevalence in 43% of trials, compared with 33% for men, across industry-sponsored Phase I–III studies.

The consequences are visible across fields:

• Oncology: Nearly 40% of cancer trials under-enrolled women by more than five percentage points, despite well-documented sex differences in tumour biology, pharmacokinetics, and toxicity profiles.
• Neurodegenerative disease: Alzheimer’s disease affects women disproportionately, accounting for roughly two-thirds of global prevalence and disease burden. Yet women make up only about half of trial participants overall – and just 40% in pivotal trials supporting drug approvals.

These gaps persist not because the evidence is unclear, but because trial designs continue to treat sex differences as secondary rather than foundational.

Psychedelic compounds often produce nuanced, domain-specific effects on mood, cognition, emotional processing, and subjective experience. These outcomes are already difficult to quantify. Adding unmeasured hormonal variability on top virtually guarantees signal dilution.

Sex hormones such as estradiol and progesterone modulate serotonergic, dopaminergic, glutamatergic, and GABAergic pathways – the very networks psychedelics interact with. When those hormones fluctuate across the menstrual cycle, postpartum period, or perimenopause, it is reasonable to expect that psychedelic effects, risks, and benefits may shift as well.

Yet most psychedelic studies either exclude women at key reproductive stages or record their participation without tracking cycle phase, contraception use, or life-stage context. In practice, this means a participant in the late luteal phase, someone using hormonal contraception, and a perimenopausal woman may all be analysed as if their biology were interchangeable.

This is not conservative science. It is a systematic risk of false negatives.

Timing matters: cycles, life phases, and misread outcomes

The problem is not only sex – it is time.

Oestrogen and progesterone fluctuate across the menstrual cycle and across life phases, each associated with distinct neuropsychological profiles. Evidence from adjacent fields, including SSRI response, ketamine research, and hormonal psychiatry, shows that treatment effects can vary meaningfully depending on cycle phase and hormone status. Psychedelics, which strongly influence serotonin signalling and neuroplastic processes, are unlikely to be exempt.

Ignoring this has practical consequences:

• Outcome measures may reflect hormone-driven symptom shifts rather than treatment effects.
• Fixed dosing schedules assume a 28-day cycle that many women do not have.
• Participants with premenstrual symptom exacerbation (PME or PMDD) may worsen transiently or disengage – misinterpreted as adverse effects or non-response rather than predictable biology.

When this happens, promising interventions are put at risk, and women’s real responses remain invisible.

Better data doesn’t require perfection – just intention

The good news is that designing better psychedelic trials for women does not require impossible precision.

At a basic level, studies can routinely document menstrual status, cycle regularity, hormonal contraception use, and life phase (menstruating, perimenopausal, menopausal). Simple cycle tracking – via diaries or apps – can contextualise dosing and outcome assessments. Where feasible, stratifying or scheduling interventions and endpoints by cycle phase can dramatically reduce noise without excluding participants. Statistical models can adjust for cycle-related variability rather than averaging it away.

Collecting structured, real-world data on women’s psychedelic use – linked to cycles, reproductive history, symptoms, and context – would go even further. It would help identify when women may be more sensitive, when adverse events are more likely, and when treatments may be especially effective. Crucially, it would provide future clinicians and facilitators with decision-making tools grounded in evidence rather than guesswork.

A narrow window and a critical responsibility

Psychedelic medicine is moving fast. Trials are advancing, regulators are paying attention, and protocols are beginning to harden into standards. There is a brief window now to ensure those standards are built around biological reality rather than retrofitted around a male default years later.

Designing psychedelic research with women’s biology in mind is not about adding complexity for its own sake. It is about improving validity, reducing false negatives, and ensuring we do not overlook treatments that work – just not uniformly, and not all the time.

At Hystelica, we believe that psychedelic science can only fulfil its promise if it reflects the bodies and lives of the people it aims to serve. That means treating sex, hormones, and life stage not as confounders, but as sources of insight.

If psychedelic medicine is to be precise, ethical, and truly inclusive, women’s biology must move from the margins to the methodology.

What you can do

• Follow and support Hystelica’s research as we work to build an evidence base centred on women’s lived and biological realities.
• Join our newsletter or educational programmes to stay informed about responsible, gender-aware psychedelic science and practice.

1. IQVIA Institute for Human Data Science. Assessing Sex and Gender Parity in Life Sciences: 2025 Summary Report.
   https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/assessing-sex-and-gender-parity-in-life-sciences/iqvia-institute-gender-2025-summary.pdf
2. Females in Psychedelic Research: A Perspective for Advancing Research and Practice
   Zahira Ziva Cohen and Grace Blest-Hopley
   ACS Pharmacology & Translational Science 2025 8 (7), 1837-1846
   DOI: 10.1021/acsptsci.5c00255

​